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In this study we evaluated the neurotoxicity of eslicarbazepine acetate (ESL), and of its in vivometabolites
eslicarbazepine (S-Lic) and R-licarbazepine (R-Lic), as compared to the structurally-related compounds
carbamazepine (CBZ) and oxcarbazepine (OXC), in an in vitromodel of cultured rat hippocampal neurons.
The non-related antiepileptic drugs (AEDs) lamotrigine (LTG) and sodium valproate (VPA) were also stud-
ied. We assessed whether AEDs modulate pro-survival/pro-apoptotic pathways, such as extracellular-
regulated kinase (ERK1/2), Akt and stress activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).
We found that neither ESL nor its metabolites, CBZ or LTG, up to 0.3 mM, for 24 h of exposure,
decreased cell viability. OXC was the most toxic drug decreasing cell viability in a concentration-depen-
dent manner, leading to activation of caspase-3 and PARP cleavage. VPA caused the appearance of the
apoptotic markers, but did not alter cell viability. ESL, S-Lic and OXC decreased the levels of phospho-
ERK1/2 and of phospho-Akt, when compared to basal levels, whereas CBZ decreased phospho-SAPK/
JNK and phospho-Akt levels. LTG and VPA increased the phosphorylation levels of SAPK/JNK.
These results suggest that ESL and its main metabolite S-Lic, as well as CBZ, LTG and VPA, are less toxic
to hippocampal neurons than OXC, which was the most toxic agent.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
A number of antiepileptic drugs (AEDs) are available for the
treatment of epilepsy, bipolar disorder, migraine, mania, neuro-
pathic pain, schizophrenia and anxiety (Rogawski and Loscher,
2004; Stefan and Feuerstein, 2007). However, some AEDs are en-
dowed with unfavourable safety profiles, such as hepatotoxicity,toxicity to central nervous system (CNS) and show complex
drug/drug interactions (Johannessen Landmark and Patsalos,
2010; Loring et al., 2007; Pennell, 2008). In recent years, pharma-
ceutical companies have developed new AEDs with improved
safety profiles than the previously available ones. Several studies
have described the toxicity of AEDs to neuronal cells, in vitro and
in vivo, (Bittigau et al., 2002; Chateauvieux et al., 2010; Landmark
and Johannessen, 2008; Manent et al., 2008), but the mechanisms
underlying the toxic effects of AEDs in neuronal cells are still a
matter of debate.
Carbamazepine (CBZ) is one of the most prescribed AED,
although it is endowed with considerable adverse effects (Albani
et al., 1995; Elger and Bauer, 1998). In the last two decades, two
other dibenz[b,f]azepine derivatives were approved as anticonvul-
sants, first oxcarbazepine (OXC) in 1990 (Elger and Bauer, 1998),
and more recently eslicarbazepine acetate (ESL) in 2009 (Elger
et al., 2009; McCormack and Robinson, 2009). Both drugs were
developed with the aim to improve efficacy and tolerability
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derivatives, CBZ, OXC and ESL, are structurally related and exert
their primary antiseizure activity by blocking voltage-gated so-
dium channels (VGSC) in neuronal membranes that are responsible
for action-potential generation (Parada and Soares-da-Silva, 2002).
Despite not being their main targets, these AEDs also act on other
receptors, such as the metabotropic receptors that are involved in
intracellular signaling pathways (Bittigau et al., 2002), pointing to
the relevance of studying their possible effects on pro-apoptotic/
pro-survival pathways.
OXC and ESL were developed as structural derivatives of CBZ,
but there are striking differences in their metabolism, mainly be-
tween CBZ and ESL. ESL is structurally different at the 10,11-posi-
tion, and consequently, it is not metabolized to CBZ-10,11-epoxide
and, therefore, it is not susceptible to enzyme induction or autoin-
duction (Bialer, 2006). Moreover, ESL is a once-daily AED (Almeida
and Soares-da-Silva, 2007) that is rapidly absorbed and undergoes
extensive first-pass metabolism, in humans (Almeida et al., 2005)
and mice (Alves et al., 2007), to its main active metabolite,
eslicarbazepine (S-Lic), which is responsible for approximately
95% of total systemic drug exposure, and to a lesser extent to R-
licarbazepine (R-Lic) and OXC, (Almeida et al., 2005). Our group
previously demonstrated that ESL is less toxic to cultured neurons
than CBZ and OXC, namely at high concentrations (0.3 mM). In-
deed, ESL did not induce apoptosis or caused structural damage
to the neuritic network (Ambrosio et al., 2000; Araujo et al.,
2004), whereas CBZ was found to induce apoptosis in cultured cer-
ebellar granule cells (Gao et al., 1995; Nonaka et al., 1998) and OXC
increased the activity of caspase-3-like enzyme (Ambrosio et al.,
2000). However, the effect of ESL metabolites, S-Lic and R-Lic, on
the viability of neuronal cells, has not been addressed yet, and it
is of interest to determine the direct effects of S-Lic and R-Lic on
the viability of cultured neurons, since in the in vitro system (cul-
tured neurons) there is no metabolism of ESL as it occurs in vivo.
Lamotrigine (LTG) also exerts its anticonvulsive action by block-
ing voltage-gated sodium channels, but is chemically unrelated to
any of the above referred AEDs (Kuo, 1998; Xie et al., 1995). LTG
was approved in the United States in 1994 and is an effective
and well-tolerated drug with few adverse effects and low toxicity
at CNS. In the neonatal rat brain, LTG did not induce neuronal
apoptosis (Katz et al., 2007) and has been reported to have neuro-
protective effects (Willmore, 2005).
Valproate (VPA), first approved in Europe in the early 1960s, has
become the most prescribed AED worldwide despite its debatable
effectiveness (Perucca, 2002). It is a broad spectrum AED with a
simple structure of a short, branched fatty acid but with various
mechanisms of action. VPA enhances GABAergic neurotransmis-
sion (Johannessen and Johannessen, 2003; Loscher, 2002), modu-
lates brain metabolism, decreases excitability by affecting
intracellular signaling pathways (Rogawski and Loscher, 2004),
and affects voltage-gated sodium, potassium and calcium channels
(Johannessen and Johannessen, 2003). VPA induces apoptotic neu-
rodegeneration in the developing rat brain and reduces the levels
of phosphorylated ERK 1/2 and Akt (Bittigau et al., 2003). Recently,
Wang and colleagues (2012) showed that VPA selectively induces
apoptosis in neurons in mixed neuron–astrocyte cultures from hu-
man fetal neural progenitors (Wang et al., 2012). However, in vitro
studies described opposite effects of VPA, showing that VPA pro-
motes the phosphorylation of ERK 1/2, Akt and SAPK/JNK, which
may ultimately be responsible for its neuroprotective effects (Chu-
ang, 2005; Di Daniel et al., 2005; Mora et al., 1999).
In the present study, we compared the effects of ESL, of its
metabolites S-Lic and R-Lic, and the structurally-related com-
pounds CBZ and OXC, as well as those of the non-related com-
pounds LTG and VPA, on the survival of primary cultures of rat
hippocampal neurons and addressed possible mechanismsunderlying their neurotoxic effects. We also assessed whether
the AEDs modulate pro-survival/pro-apoptotic pathways such as
extracellular-regulated kinase (ERK1/2), Akt and stress activated
protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling path-
ways. This work contributes to clarifying some of the mechanisms
involved on the effects of AEDs on neuronal viability in an in vitro
model of cultured hippocampal neurons.2. Material and methods
2.1. Animals
Wistar rats were obtained from Charles River (Barcelona, Spain)
and kept in our animal facilities (Faculty of Medicine, University of
Coimbra, Portugal), in a room with controlled temperature
(21 C ± 1 C) and humidity (55%), with food and water ad libitum
in a 12 h dark:light cycle. All experiments were performed in
accordance with Institutional and European guidelines (86/609/
EEC) for the care and use of laboratory animals.2.2. Primary rat hippocampal cultures
Hippocampal neurons were dissociated from the hippocampus
of E17–E18 Wistar rat embryos, after treatment with trypsin
(2.0 mg/ml, 15 min, 37 C) and deoxyribonuclease I (DNase I,
0.15 mg/ml) in calcium- and magnesium-free Hank’s balanced salt
solution (137 mM NaCl, 5.36 mM KCl, 0.44 mM KH2PO4, 0.34 mM
Na2PO42H2O, 4.16 mM NaHCO3, 5 mM glucose, 1 mM sodium
pyruvate, 10 mM HEPES, pH 7.4). The cells were cultured in ser-
um-free Neurobasal medium, supplemented with B27 supplement,
glutamate (25 lM), gentamicin (0.12 mg/ml), as described previ-
ously (Ambrosio et al., 2000; Araujo et al., 2004; Brewer et al.,
1993) and GlutaMAX™ (0.5 mM). Cultures were kept at 37 C in
a humidified incubator in 5% CO2/95% air, for 7–8 days. The cells
were plated on poly-D-lysine-coated (0.1 mg/ml) multiwells at a
density of 0.1  106 cells/cm2 for cell viability studies and Western
blot analysis, and plated on glass coverslips at a density of
0.075  106 cells/cm2 for immunocytochemistry.2.3. Exposure of hippocampal neurons to the drugs
The hippocampal neurons were exposed to AEDs for 24 h, as
previously described (Ambrosio et al., 2000; Araujo et al., 2004),
or for other periods as indicated in the figure legends. The drugs
were prepared in DMSO (except VPA, which was prepared in
water), and further diluted in 200 ll aliquots of culture medium ta-
ken from each well and then added back to the correspondent well.
In control conditions, the same concentrations of DMSO were uti-
lized for all the situations tested and did not affect cell viability.2.4. Analysis of cell viability and nuclear morphology
Cell viability was assessed in cultured hippocampal neurons,
following treatment with different concentrations of AEDs for
24 h, using the resazurin reduction assay, as described previously
(Araujo et al., 2007). Briefly, resazurin reduction was measured
spectrophotometrically at 570 and 600 nm, following incubation
of the cells with 300 ll of 10% resazurin in Krebs buffer (132 mM
NaCl, 4 mM KCl, 1.4 mM MgCl2, 1 mM CaCl2, 6 mM glucose,
10 mM Hepes-Na, pH 7.4), for 2 h at 37 C, in the dark. All experi-
ments were carried out in triplicate, and the results are expressed
as percentage of control. Cell death was also assessed by evaluating
the degree of nuclear condensation/fragmentation, after nuclear
labeling with Hoechst 33342, as described below.
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The cells were washed and lysed at 4 C in 50 mM KCl, 50 mM
PIPES, 10 mM EGTA, 2 mMMgCl2, 0.5% Triton X-100, supplemented
with 100 lM phenylmethylsulphonyl fluoride, 1 mM dithiothrei-
tol, 1 lg/ml chymostatin, 1 lg/ml leupeptin, 1 lg/ml antiparin,
5 lg/ml pepstatin A, 1 lg/ml orthovanadate, 10 lg/ml NaF, pH
7.4, at 4 C. Protein concentration was determined by the bicinch-
oninic acid (BCA) method (BCA™ Protein Assay kit, Pierce, Fisher
Scientific, Loures, Portugal), and the samples were denatured fol-
lowing addition of 6x concentrated sample buffer (0.5 M Tris,
30% glycerol, 10% SDS, 0.6 M DTT, 0.012% bromophenol blue). After
heating for 5 min at 95 C, the samples were stored at 20 C until
analysis.
2.6. Western blot analysis
Following lysis and denaturation of the samples, equal amounts
of protein were separated by electrophoresis on sodium dodecyl
sulphate polyacrylamide gels, and transferred electrophoretically
to polyvinylidene difluoride membranes. These were then blocked
for 1 h at room temperature in Tris-buffered saline (137 mM NaCl,
20 mM Tris–HCl, pH 7.6) containing 0.1% Tween 20 (TBS-T) and 5%
non-fat milk (or 3% BSA, for the analysis of phospho-proteins). All
primary antibodies used were from Cell Signaling (Danvers, MA,
USA) as follows: rabbit anti-cleaved poly ADP-ribose polymerase
(PARP), 1:1000; rabbit anti-cleaved caspase-3 1:1000; rabbit
anti-phospho SAPK/JNK (Thr183/Tyr185) 1:1000, rabbit anti-
SAPK/JNK, 1:1000; rabbit anti-phospho p44/p42 MAPK (ERK 1/2)
(Thr202/Tyr204) 1:1000; mouse anti-p44/42 MAPK (ERK 1/2)
(3A7) 1:2000; rabbit phospho-Akt (Ser473) 1:1000, rabbit phos-
pho-Akt (Thr308) 1:1000; and rabbit anti-Akt (pan) (11E7)
1:1000, in TBS-T 1% non-fat milk (or 1% BSA for phospho-proteins),
and were incubated overnight, at 4 C. After extensive rinsing in
TBS-T, the membranes were incubated for 1 h at room temperature
with an alkaline phosphatase-linked secondary antibody (anti-
mouse or anti-rabbit IgG 1:20,000) in TBS-T 1% non-fat milk (or
0.5% BSA for phospho-proteins). Immunoreactive bands were visu-
alized with ECF in a VersaDoc 3000 imaging system (BioRad,
Amadora, Portugal), following incubation of the membrane with
the ECF reagent for 5 min. Protein loading controls were either per-
formed using antibodies against the total protein in study (total
ERK 1/2, total Akt and total SAPK/JNK), or against a-tubulin
(55 kDa) (1:10,000).
2.7. Immunocytochemistry
The culture medium was removed from the primary hippocam-
pal cultures, the cells were rinsed three times with phosphate-buf-
fered saline (PBS), and then fixed with 4% paraformaldehyde, at
room temperature, for 20 min. Non-specific binding was blocked
with 3% BSA in PBS for 1 h. Cells were incubated with the primary
antibody for 90 min, at room temperature. After rinsing with PBS,
the cells were incubated with the appropriate secondary antibody
for 1 h (1:200, anti-rabbit IgGs conjugated with Alexa Fluor 594) at
room temperature. All antibodies were prepared in blocking solu-
tion. Nuclei were counterstained with Hoechst 33342 (2 lg/ml) for
5 min, followed by rinsing in PBS. The coverslips were mounted on
Dako fluorescent mounting medium in microscopy glass slides,
and images were acquired in a laser scanning confocal microscope
(LSM 510 META, Zeiss). Cells from seven to ten randomly selected
fields of each coverslip were counted using Photoshop (version
CS3; ASI, CA, USA), which represents approximately 900–1,200
cells per coverslip. Data was expressed as percentage of the total
number of nuclei, counterstained with Hoechst 33342. The
primary antibody and dilution used was: rabbitanti-apoptosis-induncing factor (AIF) antibody, 1:100 (Cell Signal-
ing, Isaza, Carnaxide, Portugal).
2.8. Data analysis
Data are expressed as means ± SEM. Statistical significance was
determined by one-way analysis of variance (ANOVA), followed by
Dunnett’s post-test, and two-way analysis of variance (ANOVA),
followed by Bonferroni’s post-test.
2.9. Materials
ESL, S-Lic, R-Lic, OXC and CBZ were obtained from BIAL–Portela
& Cª S.A. (S. Mamede do Coronado, Portugal). NEUROBASAL™Med-
ium, B27 supplement, GlutaMAX™, trypsin and gentamicin were
purchased from GIBCO (Invitrogen™, Alfagene, Carcavelos, Portu-
gal). Deoxyribonuclease 1 (DNase-1), resazurin, PMSF, dithiothrei-
tol, chymostatin, leupeptin, antipain, pepstatin A and trypan blue
were purchased from Sigma–Aldrich (Madrid, Spain). LTG and
VPA were obtained from Tocris Bioscience (Biogen Scientifca, S.L.,
Madrid, Spain). Bovine serum albumin was obtained from Calbio-
chem (VWR, Carnaxide, Portugal). Hoechst 33342 and anti-rabbit
IgGs labeled with Alexa Fluor 594 were purchased from Molecular
Probes (Invitrogen™, Alfagene, Carcavelos, Portugal). PVDF mem-
branes and the Enhanced Chemifluorescence (ECF) reagent were
obtained from Amersham Pharmacia Biotech (GE Healthcare, Car-
naxide, Portugal). Other reagents used in immunoblotting experi-
ments were purchased from BioRad (Sintra, Portugal).3. Results
3.1. Evaluation of the toxicity profile of antiepileptic drugs in cultured
hippocampal neurons
We first investigated whether ESL and its metabolites, S-Lic and
R-Lic, as well as the other AEDs affect cell viability. Cultured hippo-
campal neurons were exposed to the AEDs for 24 h, at concentra-
tions of 0.01, 0.03, 0.1 and 0.3 mM (for ESL, S-Lic, R-Lic, CBZ, OXC
and LTG) and of 0.01, 0.03, 0.1, 0.3, 0.5, 1 and 3 mM for VPA. The
concentrations of the AEDs that were utilized in these study are
within the range of those tested in functional assays using rat hip-
pocampal neurons, namely for the evaluation of effects upon Ca2+
and Na+ channels (Ambrosio et al., 1999; Ambrosio et al., 2000;
Brady et al., 2011; Hebeisen et al., 2011) and in hippocampal neu-
ral progenitor cells (Hsieh et al., 2004).
The viability of hippocampal neurons determined after expo-
sure to ESL or its metabolites (for all the concentrations tested)
was not significantly altered comparing to control conditions
(Fig. 1A–C). Furthermore, treatment of hippocampal neurons with
CBZ or LTG did not significantly affect neuronal viability for the
concentrations tested (Fig. 1D and F). VPA, which is both chemi-
cally and pharmacologically unrelated to the dibenz[b,f]azepine
derivatives, also did not alter the viability of the hippocampal neu-
rons (Fig. 1G). However, OXC significantly changed the viability of
hippocampal neurons, in a concentration-dependent manner,
decreasing cell viability to 93.2 ± 2.3% (p < 0.05) and 86.3 ± 2.9%
(p < 0.01) of the control, for 0.1 and 0.3 mM, respectively
(Fig. 1E). Lower concentrations of OXC (0.01 and 0.03 mM) did
not affect cell viability. The observed toxic effects caused by high
concentrations of OXC on the hippocampal neurons are in agree-
ment with previous studies (Ambrosio et al., 2000; Araujo et al.,
2007).
Nuclear condensation/fragmentation, which is a hallmark of cell
death, was next analysed in cultured hippocampal neurons ex-
posed to AEDs for 24 h, for the higher concentration tested in the
Fig. 1. Effect of exposure to AEDs on the viability of cultured hippocampal neurons. Hippocampal neurons were exposed to increasing concentrations of AEDs for 24 h:(A) ESL,
(B) S-Lic, (C) R-Lic, (D) CBZ, (E) OXC, (F) LTG, and (G) VPA, and cell viability was evaluated, by the resazurin reduction assay. The results are presented as percentage of control
(no drug), and represent the means ± SEM of at least four independent experiments performed in triplicate in different cultures. p < 0.05; p < 0.01, significantly different
from control, one-way ANOVA, Dunnett’s post-test. ESL, eslicarbazepine acetate; S-Lic, eslicarbazepine; R-Lic, R-licarbazepine; CBZ, carbamazepine; OXC, oxcarbazepine; LTG,
lamotrigine; VPA, valproate.
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trol cultures, 21.4 ± 1.4% of total cells presented condensed/frag-
mented nuclei, which is in agreement to previous studies
showing similar basal levels of cell death in hippocampal cultures
(Almeida et al., 2005; Araujo et al., 2007). Exposure to ESL, S-Lic, R-
Lic, CBZ, LTG or VPA did not increase the percentage of condensed/
fragmented nuclei (p > 0.05) (Supplementary data, Fig. 1). How-
ever, treatment with OXC (0.3 mM) significantly increased the per-
centage of cells showing nuclear condensation/fragmentation to
37.1 ± 6.0% (p < 0.01) (Supplementary data, Fig. 1B).
3.2. Cell exposure to OXC or VPA increased apoptotic markers in
cultured hippocampal neurons
We next investigated the presence of apoptotic markers, such as
activation of caspase-3, the main effector caspase in apoptotic cell
death, which is activated by proteolytic cleavage of full-lengthcaspase-3 (32 kDa), producing fragments of 17/19 kDa. The pres-
ence of these fragments can be used as a marker for caspase-3 acti-
vation. For this purpose, an antibody that selectively recognizes the
breakdown products (17/19 kDa), but not full-length caspase-3,
was used. Cultured hippocampal neurons were exposed to the
AEDs for 24 h at 0.3 mM (except for VPA that was used at 3 mM).
We detected cleavage of caspase-3 in cultures exposed to OXC or
VPA. Treatment with OXC caused a 5-fold increase in cleaved cas-
pase-3 levels (p < 0.001), whereas VPA caused a 2-fold (p < 0.01) in-
crease, when compared to the control (Fig. 2). Exposure of the cells
to ESL, S-Lic, R-Lic, CBZ or LTG, did not increase the cleavage of cas-
pase-3, as detected by Western blotting.
PARP is a downstream substrate of caspase-3 and a powerful
effector of cell death, causing ATP depletion; the presence of an
89 kDa fragment is indicative of PARP cleavage. We next investi-
gated the profile of PARP cleavage in neurons treated with the
AEDs. Cell exposure to OXC or VPA, but not to the other AEDs,
Fig. 2. Levels of cleaved caspase-3 in hippocampal neurons following exposure to
AEDs. Hippocampal neurons were exposed for 24 h to AEDs (0.3 mM for all AEDs
and 3 mM for VPA). Representative Western blots and quantification of the levels of
the 17/19 kDa cleavage product of caspase-3 are shown. Levels of cleaved caspase-3
were significantly higher in cultures treated with OXC and VPA than in control
(Ctrl). a-Tubulin (55 kDa) was used as a loading control. The results are presented
as percentage of control, and represent means ± SEM of at least 4 independent
experiments performed in different cultures. p < 0.001, significantly different
from control, one-way ANOVA, Dunnett’s post-test. Abbreviations of the AEDs as
indicated in the legend of Fig. 1.
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and to 218.0 ± 23.2% (p < 0.01) of the control, respectively, as eval-
uated by Western blot analysis (Fig. 3).
Translocation of AIF from the mitochondria to the nucleus may
occur in the caspase-independent apoptotic pathway (Joza et al.,
2001). In AED-treated cultures, AIF was detected by immunocyto-
chemistry in the cytoplasm of either viable or dying neurons. Cells
treated with ESL and its metabolites, or the other AEDs, did not
show evidence of nuclear translocation of AIF in any case. This fac-
tor showed a cytosolic localization even though condensed/frag-
mented nuclei were quite evident in OXC-treated cells (0.3 mM)
(Supplementary data, Fig. 2). Thus, AIF does not appear to be in-
volved in cell death triggered by exposure of hippocampal neurons
to OXC, pointing to a caspase-dependent apoptotic pathway in-
duced by this AED.Fig. 3. Levels of cleaved PARP in hippocampal neurons following exposure to AEDs.
Hippocampal neurons were exposed for 24 h to AEDs. The concentrations for each
AED were the same as those described in the legend of Fig. 2. Representative
Western blots and quantification of the levels of 89 kDa cleavage product of PARP
are presented for each AED. Levels of cleaved PARP were significantly higher in
cultures treated with OXC and VPA than in control. a-Tubulin (55 kDa) was used as
a loading control. The results are presented as percentage of control, and represent
means ± SEM of at least 4 independent experiments performed in different cultures.
p < 0.001, p < 0.01, significantly different from control, one-way ANOVA,
Dunnett’s post-test. Abbreviations of the AEDs as indicated in the legend of Fig. 1.3.3. Effects of antiepileptic drugs on signaling pathways related to
neuronal injury/survival
In order to examine whether the effects of the AEDs presented
above are related to changes in pro-survival/pro-apoptotic path-
ways in cultured hippocampal neurons, we next studied the activa-
tion of extracellular-regulated kinase (ERK 1/2; p44/p42), Akt and
stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/
JNK; p54/p46). The phosphorylation levels of these kinases were
analysed by Western blot at different time points, for short-term
exposures up to 60 min, and for a longer period of 24 h of incuba-
tion with each of the AEDs (0.3 mM for ESL, S-Lic, R-Lic, CBZ, OXC
and LTG; 3 mM for VPA). The phosphorylated forms of those ki-
nases were differently affected, as described below.
In cultured hippocampal neurons exposed to ESL or S-Lic, the
levels of phospho-ERK 1/2 decreased, as compared to control con-
ditions (Fig. 4A and B). The levels of phospho-ERK 1/2 decreased to
39.7 ± 8.4% for ESL and to 54.0 ± 9.8% for S-Lic (p < 0.01), 60 min
following exposure to the drug. Phosphorylation of ERK 1/2 was
still decreased 24 h after treatment with ESL, but was similar to
control levels 24 h after exposure to S-Lic. Exposure to R-Lic, CBZ
or LTG did not significantly affect the levels of phospho-ERK 1/2,
(p > 0.05) (Fig. 4C, D, F). Exposure to OXC for 30 or 60 min caused
a significant decrease in phosphorylated ERK 1/2 (61.62 ± 4.8 and
58.27 ± 6.01%, respectively, p < 0.05) (Fig. 4E). In contrast, 30 min
after exposure to VPA, there was an increase in phospho-ERK 1/2
to 144.4 ± 2.6% (p < 0.05) (Fig. 4G). Concerning the activation of
Akt, in this study we evaluated possible changes in the phosphor-
ylation of both serine 473 (Ser473) and threonine 308 (Thr308)
residues. The results of Western blot analysis indicated significant
changes on the levels of phosphorylation only in the Thr308 resi-
due, following exposure of hippocampal neurons to AEDs (Fig. 5).
Thus, ESL caused a significant decrease in phospho-Thr308 to
50.2 ± 4.6% (p < 0.05) after 1 h of treatment (Fig. 5A). S-Lic pro-
duced a similar effect, but earlier, at 30 min (Fig. 5B). R-Lic only de-
creased phosphorylation of Thr308 after 24 h of exposure to the
drug (Fig. 5C). CBZ decreased Thr308 phosphorylation
(47.9 ± 16.8%, p < 0.01) after 60 min of exposure (Fig. 5D). Exposure
to OXC caused a time-dependent decrease in phospho-Thr308, up
to 24 h of exposure (45.12 ± 6.5%, of the control, p < 0.01)
(Fig. 5E). LTG did not significantly alter Akt phosphorylation
(Fig. 5F). However, VPA significantly increased the phosphorylation
of Thr308 after 60 min of exposure (202.3 ± 25.9%, of the control,
p < 0.001), but this effect was lost at 24 h of exposure to VPA
(Fig. 5G).
We also analysed the levels of phospho-SAPK/JNK. It was ob-
served that neither ESL nor its metabolites caused changes in the
phosphorylation levels of either isoform of SAPK/JNK, p54 and
p46 (Fig. 6A–C). The same was observed in cells exposed to OXC
(Fig. 6E). On the other hand, CBZ decreased the levels of phos-
pho-p46 by approximately 70% (p < 0.01) up to 60 min after expo-
sure (Fig. 6D). Exposure to LTG for 60 min caused a significant
increase in the phospho levels of both isoforms (137.2 ± 10.5% for
phospho-p54, and 137.5 ± 9.8% for phospho-p46, p < 0.05), which
remained elevated by 2-fold after 24 h exposure (194.0 ± 17.6%
for phospho-p54, and 198.8 ± 28.4% for phospho-p46, p < 0.001)
(Fig. 6F). Exposure to VPA for 24 h also caused an increase in phos-
pho-p46 to 136.2 ± 16.8% of the control (p < 0.05) (Fig. 6G).4. Discussion
AEDs interact primarily with neurotransmitters receptors or ion
channels, and they may directly or indirectly interfere with intra-
cellular proteins and signaling systems. Also, AEDs can induce neu-
ronal cell death by triggering apoptotic neurodegeneration in
Fig. 4. Analysis of phospho-ERK 1/2 (p44/p42) in hippocampal neurons following exposure to AEDs. Representative Western blots for phospho-ERK 1/2 and total ERK 1/2 are
shown, as well as quantification of the levels of phospho-ERK 1/2 following exposure to AEDs for the periods indicated. The concentrations for each AED were the same as
those described in the legend of Fig. 2. The results are presented as percentage of control, after normalization of the data for total ERK 1/2 levels, and represent means ± SEM of
at least 3 independent experiments performed in different cultures. p < 0.05, p < 0.01, significantly different from control, one-way ANOVA, Dunnett’s post-test.
Abbreviations of the AEDs as indicated in the legend of Fig. 1.
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ney et al., 2002). There is no information about the potential toxic
effects triggered by ESL metabolites and by LTG in cultured hippo-
campal neurons. The present data show that neither ESL nor its
metabolites, S-Lic and R-Lic, or LTG, caused any toxicity to cultured
hippocampal neurons. OXC was the most toxic compound in all as-
says, particularly at high concentrations, and VPA also induced the
appearance of apoptotic markers in hippocampal cultures.Exposure to OXC (0.1 and 0.3 mM) for 24 h increased cell death
in hippocampal neurons. Activation of caspase-3 and PARP cleav-
age was also evident following treatment with OXC. However,
ESL, S-Lic, R-Lic or LTG had no effect, up to 0.3 mM, on the viability
of cultured hippocampal neurons, according to the parameters
evaluated in this study. OXC stands out as the most toxic drug eval-
uated, which is in agreement with previous studies in hippocampal
neurons (Ambrosio et al., 2000; Araujo et al., 2004). In a previous
Fig. 5. Analysis of phospho-Akt (Thr308/Ser473) in hippocampal neurons following exposure to AEDs. Representative Western blots for phospho-Akt and total Akt are shown
in each pannel, as well as the quantification of the levels of each Akt phospho-residue (Thr308, white bar and Ser473, black bar), following exposure to AEDs for the periods
indicated. The concentrations for each AED were the same as those described in the legend of Fig. 2. The results are presented as percentage of control, after normalization of
the data for total Akt levels, and represent means ± SEM of at least 3 independent experiments performed in different cultures. p < 0.05, p < 0.01, p < 0.001, significantly
different from control, two-way ANOVA (time and residue as factors), Bonferronis’s post-test. Abbreviations of the AEDs as indicated in the legend of Fig. 1.
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gered a loss of the mitochondrial membrane potential. Since the
release of AIF from the mitochondria and its translocation to the
nucleus occurs after mitochondrial depolarization (Zhang et al.,
2002), we examined whether AIF could be a player in the toxic ef-
fect of OXC in hippocampal neurons. Interestingly, the transloca-
tion of AIF to the nuclei of dying hippocampal neurons exposed
to OXC was not observed (nor in cells treated with the other AEDs),
even though apoptotic nuclei were quite evident in OXC-treated
cells. Since this protein does not seem to be involved in the cell
death triggered by exposure to OXC in hippocampal neurons, it is
plausible that cell death observed after exposure to OXC may be
caspase-dependent.Exposure of hippocampal neurons to OXC (0.3 mM) or VPA
(3 mM) caused an increase in caspase-3 activation, and also in
PARP cleavage. However, cell death was not observed after VPA
exposure when looking at nuclear condensation/fragmentation,
and cell viability was not decreased by this drug. One possible
explanation for the lack of cell death (despite some indication of
apoptosis such as the presence of cleaved caspase-3) is that cas-
pase-3 cleavage occurs earlier in the cell death cascade than nucle-
ar condensation and changes in the redox capacity of the cells.
Thus, although a clear decrease in cell viability is not yet detected
by these methods, caspase-3 has already been activated and the
cell death cascade was set into motion. Stimulation of cell survival
pathways concomitantly with cleavage of caspase-3 may prevent
Fig. 6. Analysis of phospho-SAPK/JNK in hippocampal neurons following exposure to AEDs. Representative Western blots for phospho-SPAK/JNK and total SAPK/JNK are
shown in each pannel, as well as the quantification of the levels of phospho-p46 (black bar) and phospho-p54 (white bar) following exposure to AEDs for the periods
indicated. The concentrations for each AED were the same as those described in the legend of Fig. 2. The results are presented as percentage of control, after normalization of
the data for total SAPK/JNK levels, and represent means ± SEM of at least 3 independent experiments performed in different cultures. p < 0.05 and p < 0.01, p < 0.001,
significantly different from control, two-way ANOVA (time and isoforms as factors), Bonferroni’s post-test. Abbreviations of the AEDs as indicated in Fig. 1.
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cleavage is detectable, it is not associated to cell demise.
Mitogen-activated protein kinases (MAPKs) are activated by di-
verse stimuli such as neurotransmitters, cellular stress and growth
factors (Liu et al., 2007). ERK 1/2 (extracellular signal-regulated ki-
nase) and Jun-N-terminal kinase (JNK) also known as stress-acti-
vated protein kinase (SAPK) are two subfamilies of MAPKs. The
MAPK/ERK pathway among other features is involved in neuronal
survival. Hetman and Gozdz (2004) showed that ERK1/2 has a
pro-survival activity in neurons (Hetman and Gozdz, 2004; Het-
man et al., 1999). On the other hand, it also has a role in apoptosis,
which depends on cell type and on the signal that triggers cell
death. It was observed that persistent activation of ERK 1/2 con-
tributes to apoptosis in primary cortical neuronal cultures (Satohet al., 2000; Stanciu et al., 2000). The SAPK/JNK is a central media-
tor of stress and is essential for the regulation of physiological and
pathological processes (Johnson and Nakamura, 2007). It mediates
apoptosis by regulation of pro- and anti-apoptotic activity of mem-
bers of Bcl-2 family and gene transcription (Burke, 2007). PI3K/AKT
signaling pathway also plays a role in surviving of neurons by dif-
ferent mechanisms (Dudek et al., 1997; Yao and Cooper, 1995). Akt
is a serine/threonine kinase involved in this pathway and when
activated it mediates cell survival by inhibition of apoptosis, prolif-
eration and transcription, among other functions (Brazil and Hem-
mings, 2001), and thus deactivation of Akt accompanies cell death
induced by many different agents (Luo et al., 2003). Changes in
these signaling pathways reflect an imbalance between neuropro-
tective and neurodegenerative mechanisms in the brain that can
M.I. Morte et al. / Toxicology in Vitro 27 (2013) 2193–2202 2201induce apoptotic death (Asimiadou et al., 2005; Bittigau et al.,
2003).
In this study, we observed that CBZ did not increase neuropro-
tective signaling, and actually strongly decreased the levels of
phospho-SAPK/JNK, and to a lesser degree, also decreased the lev-
els of phospho-Akt. Possibly, for a longer exposure, the toxic effect
of CBZ would be more evident and detectable by morphological
criteria such as nuclear condensation/fragmentation, as we have
found in previous studies (Ambrosio et al., 2000; Araujo et al.,
2004). Moreover, dibenz[b,f]azepine derivatives such as OXC, ESL,
R-Lic and S-Lic also decreased the levels of phosphorylated forms
of ERK 1/2, Akt and SAPK/JNK. OXC strongly decreased the phos-
phorylation status of ERK 1/2 and Akt. A previous study by Bittigau
et al. (2002) suggested that AEDs can induce apoptosis in neurons
by inhibiting and decreasing the signaling of survival pathways
such as ERK 1/2 and Akt (Bittigau et al., 2002). ESL, S-Lic and R-
Lic also decreased the levels of phosphorylated ERK 1/2 and Akt,
however this decrease was lower than that observed with OXC
and, furthermore, these drugs did not induce any other signs of
neurotoxicity as OXC did. This suggests that ESL metabolites are
less deleterious to neuronal cells because they affect the survival
pathways to a lower extent than other AEDs, namely OXC. On
the other hand, one may speculate that these effects of ESL and
its metabolites on ERK 1/2 may constitute a compensatory re-
sponse mechanism to the marked increases in ERK activation ob-
served at the time of spontaneous seizures. In fact, in an in vivo
study, phospho-ERK levels were shown to increase after a behav-
ioural seizure detection (Houser et al., 2008). Inhibiting ERK signal-
ing might be useful for seizure control (Nateri et al., 2007).
Unless metabolic impairment or hepatic failure occurs, it is not
likely that OXC will persist in high levels in the plasma, and thus it
is not expected that it will impact on the overall survival of neuro-
nal cells in vivo. In fact, at least in humans this AED is readily con-
verted to S-Lic and R-Lic (Almeida and Soares-da-Silva, 2007).
Regarding the fact that OXC is a minor metabolite of ESL in hu-
mans, OXC accounts for less than 5% of metabolized ESL, and it is
unlikely that high concentrations of OXC as those used in this
study will reach the brain. However, in a recent study with healthy
volunteers that received ESL or OXC (Trileptal), the extent of
exposure to R-licarbazepine and OXC in plasma and cerebrospinal
fluid was approximately fourfold higher with OXC as compared
with ESL. Remarkably, a total of 84 and 24 treatment-emergent ad-
verse events (mostly CNS related) were reported with OXC and ESL,
respectively (Nunes et al., 2013). This suggests that high OXC expo-
sure may associate with more frequent and marked CNS related
adverse events. Similar differences in tolerability between healthy
volunteers receiving ESL and oxcarbazepine were reported by
Milovan et al. (2010).
It is of interest to mention here that the concentrations of AEDs
used in the present in vitro experiments are higher than those
found in patients, however they were chosen accordingly to previ-
ous studies where a large spectrum of concentrations were used to
test effects on cultured neurons (Nonaka et al., 1998; Benes et al.,
1999; Ambrosio et al., 2000; Araujo et al., 2004). In particular, the
concentrations of OXC used were near to those observed in the
plasma of humans (Almeida et al., 2008). Furthermore it is not
known whether the chronic use of the drugs in patients may lead
to their accumulation in microdomains of the nervous system
where higher concentrations than those found in the plasma may
be attained.
Interestingly, we observed that LTG strongly increased the
phosphorylation of SAPK/JNK in hippocampal neurons, which
may indicate that LTG promotes neuronal survival by this pathway,
as suggested but not fully explored by Chang and colleagues
(Chang et al., 2009). Another study has also demonstrated that
LTG does not affect the signaling of ERK 1/2 or Akt (Aubry et al.,2009), but its effect on the SAPK/JNK pathway had up to now re-
mained unaddressed. Moreover, LTG was shown to be able to pre-
vent staurosporine-induced caspase-3 activation in a neuronal cell
line (Li et al., 2002), for a concentration similar to the one used in
this study (0.3 mM). Our results support the possibility that LTG
may be a neuroprotective agent, acting through the JNK pathway.
Finally, we observed that VPA stimulated the phosphorylation
of ERK 1/2, Akt and SAPK/JNK, which may trigger neuroprotective
mechanisms. Our data are in agreement with earlier findings
showing that treatment with VPA activates ERK 1/2, Akt and
SAPK/JNK, which are ultimately responsible for its neuroprotective
effects (Chuang, 2005; Di Daniel et al., 2005; Mora et al., 1999).
In summary, it is shown that ESL and its metabolites, S-Lic and
R-Lic, up to 0.3 mM, do not induce neurotoxic effects in hippocam-
pal neurons in vitro, and the observed inhibitory effects on MAPK/
ERK pathway may be beneficial in vivo to face the overactivation of
ERK1/2 that may occur during spontaneous seizures. CBZ and LTG
were not toxic to cultured neurons at the concentrations tested
(0.03–0.3 mM), and LTG may exert neuroprotective effects through
the activation of the JNK pathway. Treatment with OXC or VPA in-
duced the appearance of markers related to cell death, and OXC
was the most toxic drug.Conflict of interest
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